Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Five years of letrozole does not improve disease free survival for pretreated...

Dr Terry Mamounas - UF Health Center, Orlando, USA

Five years of letrozole does not improve disease free survival for pretreated HR positive breast cancer ( Dr Terry Mamounas - UF Health Center, Orlando, USA )

Reducing chemo-associated hair loss with scalp cooling cap

Dr Julie Rani Nangia - Baylor College of Medicine, Houston, USA

Reducing chemo-associated hair loss with scalp cooling cap ( Dr Julie Rani Nangia - Baylor College of Medicine, Houston, USA )

Decoding breast cancer predisposition genes

Dr Fergus Couch - Mayo Clinic, Rochester, USA

Decoding breast cancer predisposition genes ( Dr Fergus Couch - Mayo Clinic, Rochester, USA )

Macrophage iron recycling in triple negative breast cancer

Dr Lisa Privette Vinnedge - Cincinnati Children's Hospital, Cincinnati, USA

Macrophage iron recycling in triple negative breast cancer ( Dr Lisa Privette Vinnedge - Cincinnati Children's Hospital, Cincinnati, USA )

Results of the BELLE-3 study of buparlisib for advanced breast cancer

Dr Ruth O'Regan - University of Wisconsin-Madison, Madison, USA

Results of the BELLE-3 study of buparlisib for advanced breast cancer ( Dr Ruth O'Regan - University of Wisconsin-Madison, Madison, USA )

Epirubicin and cyclophosphamide before docetaxel in early breast cancer

Dr Bent Ejlertsen - Rigshospitalet Copenhagen, Denmark

Epirubicin and cyclophosphamide before docetaxel in early breast cancer ( Dr Bent Ejlertsen - Rigshospitalet Copenhagen, Denmark )

Matched mutations and long term letrozole for breast cancer

Dr Virginia Kaklamani - UT Health Science Center, San Antonio, USA

Matched mutations and long term letrozole for breast cancer ( Dr Virginia Kaklamani - UT Health Science Center, San Antonio, USA )

neoMONARCH: CDK inhibition for HR positive, HER negative breast cancer

Dr Sara Hurvitz - Ronald Reagan UCLA Medical Center, Los Angeles, USA

neoMONARCH: CDK inhibition for HR positive, HER negative breast cancer ( Dr Sara Hurvitz - Ronald Reagan UCLA Medical Center, Los Angeles, USA )

Oestrogen deprivation inffective with chemo for HR/HER positive breast cancer

Dr Mothaffar Rimawi - Baylor College of Medicine, Houston, USA

Oestrogen deprivation inffective with chemo for HR/HER positive breast cancer ( Dr Mothaffar Rimawi - Baylor College of Medicine, Houston, USA )

No benefit for adjuvant ibandronate at 3 years in early breast cancer

Prof Sabine Linn - Netherlands Cancer Institute, Amsterdam, The Netherlands

No benefit for adjuvant ibandronate at 3 years in early breast cancer ( Prof Sabine Linn - Netherlands Cancer Institute, Amsterdam, The Netherlands )

PARP inhibitory velaparib trialled in BRCA1/2 breast cancer

Dr Heather Han - H. Lee Moffitt Cancer Center, Tampa, USA

PARP inhibitory velaparib trialled in BRCA1/2 breast cancer ( Dr Heather Han - H. Lee Moffitt Cancer Center, Tampa, USA )

Matched mutations in the progression of metastatic breast cancer

Dr Ofir Cohen - Broad Institute of MIT and Harvard, Cambridge, USA

Matched mutations in the progression of metastatic breast cancer ( Dr Ofir Cohen - Broad Institute of MIT and Harvard, Cambridge, USA )

More from ecancer